K

Knight Therapeutics Inc
TSX:GUD

Watchlist Manager
Knight Therapeutics Inc
TSX:GUD
Watchlist
Price: 5.29 CAD -0.19% Market Closed
Market Cap: 534.2m CAD
Have any thoughts about
Knight Therapeutics Inc?
Write Note

Knight Therapeutics Inc
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Knight Therapeutics Inc
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
K
Knight Therapeutics Inc
TSX:GUD
Additional Paid In Capital
CA$26.2m
CAGR 3-Years
7%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Bausch Health Companies Inc
TSX:BHC
Additional Paid In Capital
$201m
CAGR 3-Years
-23%
CAGR 5-Years
-13%
CAGR 10-Years
-2%
Sundial Growers Inc
NASDAQ:SNDL
Additional Paid In Capital
CA$73m
CAGR 3-Years
7%
CAGR 5-Years
50%
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
Additional Paid In Capital
$49.3m
CAGR 3-Years
15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Additional Paid In Capital
$625.5m
CAGR 3-Years
214%
CAGR 5-Years
279%
CAGR 10-Years
N/A
C
Curaleaf Holdings Inc
CNSX:CURA
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Knight Therapeutics Inc
Glance View

Market Cap
534.2m CAD
Industry
Pharmaceuticals

Knight Therapeutics Inc engages in acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. The company is headquartered in Montreal, Quebec and currently employs 660 full-time employees. The company went IPO on 2014-02-28. The firm's principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. The Company’s products include BIJUVA Estradiol and Progesterone capsule, IMVEXXY Estradiol vaginal inserts, IBSRELA Tenapanor tablets, TRELSTAR Prostate Triptorelin, TRELSTAR Endometriosis Triptorelin, ILUVIEN Fluocinolone acetonide, Nerlynx Neratinib Tablets, Nerlynx Patient Checklist, Nerlynx Prescriber Checklist, Burinex Bumetanide, Probuphine Buprenorphine implant, Movantik Naloxegol and Neuragen. The company owns Biotoscana Investments S.A., a pan-Latin American specialty pharmaceutical company. Its subsidiaries operates under United Medical, Biotoscana Farma and Laboratorio LKM.

GUD Intrinsic Value
6.31 CAD
Undervaluation 16%
Intrinsic Value
Price
K

See Also

What is Knight Therapeutics Inc's Additional Paid In Capital?
Additional Paid In Capital
26.2m CAD

Based on the financial report for Sep 30, 2024, Knight Therapeutics Inc's Additional Paid In Capital amounts to 26.2m CAD.

What is Knight Therapeutics Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
10%

Over the last year, the Additional Paid In Capital growth was 2%. The average annual Additional Paid In Capital growth rates for Knight Therapeutics Inc have been 7% over the past three years , 10% over the past five years .

Back to Top